Retinoblastoma protein expression and its predictors in triple-negative breast cancer

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

(2019) Takuro Yamamoto et al.   BREAST CANCER RESEARCH AND TREATMENT

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

(2018) G N Hortobagyi et al.   ANNALS OF ONCOLOGY

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

(2018) Séverine Guiu et al.   BRITISH JOURNAL OF CANCER

A Distinct Oncogenerative Multinucleated Cancer Cell Serves as a Source of Stemness and Tumor Heterogeneity

(2018) David Díaz-Carballo et al.   CANCER RESEARCH

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

(2018) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

(2018) Daniele Cretella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features

(2018) Kristine Astvatsaturyan et al.   PLoS One

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

(2018) Angela Santonja et al.   Oncotarget

Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer.

(2018) Tomas Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells

(2017) Chun-Yu Liu et al.   PLoS One

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-androgen therapy in triple-negative breast cancer

(2016) Valerie N. Barton et al.   Therapeutic Advances in Medical Oncology

Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers

(2014) Nadine Tung et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers

(2011) Larissa J. Lee et al.   CANCER

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy

(2009) D. Trere et al.   ANNALS OF ONCOLOGY